The circadian clock functions as a molecular anti‑aging firewall by sequestering NF‑κB away from inflammatory gene promoters through BMAL1/CLOCK binding at E‑box elements. Age‑related decline of hypothalamic SIRT1 reduces NAD+‑dependent deacetylation of both BMAL1 and the NF‑κB subunit RelA(p65), weakening clock amplitude and increasing NF‑κB transcriptional activity. We hypothesize that selective pharmacological activation of SIRT1 in the mediobasal hypothalamus will re‑establish the competitive advantage of BMAL1/CLOCK over NF‑κB at E‑box sites, thereby suppressing inflammation, restoring GnRH pulsatility, and delaying systemic aging phenotypes.

Mechanistically, SIRT1 deacetylates lysine residues on BMAL1 that enhance its DNA‑binding affinity and promote recruitment of coactivators CBP/p300 to clock‑driven transcription. Simultaneously, SIRT1 deacetylates RelA(p65) at lysine 310, reducing its transcriptional potency and promoting its export from the nucleus. When SIRT1 activity is elevated, the increased affinity of BMAL1/CLOCK for E‑boxes outcompetes RelA for limited coactivator pools, effectively sequestering NF‑κB away from inflammatory promoters. This dual action creates a bistable switch: high SIRT1 → strong clock amplitude → low NF‑κB activity; low SIRT1 → weak clock → high NF‑κB activity.

To test this hypothesis, we will generate a mouse line with inducible, hypothalamus‑specific SIRT1 overexpression (using Sim1‑CreERT2) and treat cohorts with a SIRT1‑activating compound (e.g., SRT2104) versus vehicle. Experimental groups will be aged to 18 months, with longitudinal monitoring of:

1. Circadian amplitude in the SCN and arcuate nucleus measured by PER2::LUC bioluminescence ex vivo.
2. Chromatin occupancy of BMAL1, CLOCK, and RelA at E‑box sites quantified by ChIP‑seq in microdissected mediobasal hypothalamus.
3. Levels of acetylated BMAL1 and RelA(p65) via immunoblot.
4. GnRH mRNA and pulsatile LH secretion as downstream readouts of hypothalamic output.
5. Systemic aging markers: hippocampal neurogenesis, grip strength, glucose tolerance, and survival.

Predictions: SIRT1 upregulation will increase BMAL1/E‑box binding and decrease RelA/E‑box binding within two weeks, accompanied by a ≥30 % rise in circadian amplitude. GnRH transcription will recover to ≥80 % of young adult levels, LH pulses will normalize, and downstream tissues will show improved neurogenesis and metabolic homeostasis. Consequently, median lifespan should extend by at least 15 % relative to controls. Failure to observe these changes would falsify the hypothesis, indicating that hypothalamic SIRT1 alone is insufficient to reinstate the circadian firewall or that additional nodes (e.g., IKKβ signaling, NAD+ salvage pathways) dominate the age‑related collapse. This experiment directly links a molecular intervention to the mechanistic competition described in the fire‑wall model, offering a clear, falsifiable path toward testing whether boosting hypothalamic SIRT1 can reinstate circadian‑mediated protection against inflammaging.